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Abstract
The molecular epidemiology and the genetic basis of antibiotic resistance in 88 multidrug-resistant (MDR) Acinetobacter baumannii strains
isolated during 18 months from infected patients in seven intensive care units (ICUs) in Rome were investigated. Random ampliﬁed poly-
morphic DNA and macrorestriction analysis identiﬁed two predominant clonal types, genetically related to the European epidemic clones I
(type 2) and II (type 1), accounting for 98.9% of A. baumannii ICU isolates. Type 1 was isolated from all ICUs under survey. Class 1 integrons
of 2.2 and 2.5 kb were detected in type 1 and type 2 isolates, respectively. The integron structures were similar to those previously deter-
mined for epidemic A. baumannii strains from various European countries, and suggestive of integron rearrangement/exchange among iso-
lates related to the European epidemic clones I and II. Carbapenem resistance was associated with the presence of the blaOXA-58 gene in
type 1 isolates. The results indicate that the A. baumannii type 1 clone has a high potential of spreading among hospitals.
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Introduction
Acinetobacter baumannii infection is a leading cause of morbidity
and mortality in the hospital setting, especially among critically
ill patients in intensive care units (ICUs). The epidemiology of
A. baumannii infection in ICUs is complex due to the coexis-
tence of epidemic cases with unrelated sporadic cases caused
by different strains [1,2]. Outbreaks of A. baumannii infection
in ICUs have often been attributed to transmisson via ventila-
tory equipment and to hand transmission by health care per-
sonnel [1,2]. The epidemic potential and the clinical severity of
A. baumannii infections are related to resistance of the isolates
to antimicrobial agents, including broad-spectrum b-lactams,
aminoglycosides, ﬂuoroquinolones and carbapenems [3].
A few lineages of A. baumannii have caused multiple hospital
outbreaks in different countries, and have therefore acquired
epidemic status. By convention, these lineages are termed
clones and their relatedness is assessed on a genotypic basis
[4]. Two pan-European epidemic clones of A. baumannii,
referred to as European clones I and II [5,6], became wide-
spread in north-western Europe in the years 1982–1990 [5]
and prevailed in the Czech Republic from 1991 to 2001 [6,7].
With time, clone I was isolated in Spain, Poland, the UK and
Italy, while clone II was obsrved in Spain, Portugal, France,
Greece, the UK and Turkey [8–10]. A third pan-European
A. baumannii clone, clone III, probably persisting in European
hospitals since the 1990s, has recently been described in
France, the Netherlands, Italy, and Spain [10,11].
Multidrug resistance in A. baumannii is linked to the
presence of resistance islands, mobile genetic elements and
integrons capable of capturing antibiotic resistance genes by
site-speciﬁc recombination [2,12–14]. In fact, class 1 integ-
rons with different variable regions have been identiﬁed in
pan-European clones I, II and III [11].
Few reports have been published concerning the epidemi-
ology of nosocomial A. baumannii infection in Italy [15–20],
and a systematic survey of the hospital epidemiology
and drug resistance of A. baumannii is not yet available on a
national scale. Recently, the circulation of different
A. baumannii clones, including a carbapenem-resistant one,
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has been documented in three apparently unrelated ICU out-
breaks which occurred during 2004–2005 in Rome [18–20]. In
this scenario, a network of laboratories and clinicians (Gruppo
Romano Acinetobacter baumannii (GRAB)) was created with
the aim of tracing the hospital epidemiology of A. baumannii
infection in the Rome urban area (including seven hospitals
with a total of 5392 beds, 187 of which were in ICUs), and
providing collaborating centres with outbreak alerts, anti-
biotic-resistance surveillance data and typing facilities.
This study provides an in-depth characterization of 88
multidrug-resistant (MDR) A. baumannii strains responsible
for seven ICU outbreaks in Rome, with the aim of deﬁning
their epidemiological traits and the genetic basis of antibiotic
resistance.
Materials and Methods
Bacterial isolates
A total of 90 MDR isolates, provisionally identiﬁed as A. bau-
mannii, was collected from outbreaks or sporadic cases of
infection that occurred during the 18-month investigation
period (from 7 January 2004 to 27 June 2005) in seven ICUs,
designated A, B, C, D, E, F, G, of large regional hospitals
in the Rome urban area, and submitted to the coordinating
laboratory at the National Institute for Infectious Diseases
‘Lazzaro Spallanzani’ (Rome) for further characterization
(Table 1). The index strains (study codes 97 and 115) from
previously published outbreaks were provided by hospitals F
and G [19,20], in addition to two MDR isolates recovered
from sporadic cases preceding the outbreak in hospital F.
During the outbreaks, local control of the epidemics
required urgent measures, including environmental sampling,
aggressive environmental disinfections, and, at least in two
hospitals, temporary closure of the ICU admissions.
Bacteria were routinely identiﬁed to the species level by the
participating centres using the Phoenix (Becton Dickinson,
Sparks, MD, USA) and Vitek 2 (BioMe´rieux, Marcy-l’Etoile,
France) commercial systems. Isolates were from respiratory
secretions (n = 49), central venous catheters (n = 11), urine
(n = 8), wound swabs (n = 6), blood (n = 6), and cerebrospi-
nal ﬂuid (n = 1), and were all associated with a clinical infec-
tion. Only the primary isolate of each infected patient was
included in the collection. Nine environmental isolates were
recovered from medical devices or the ICU environment of
hospitals B and C (Table 1). The two reference strains for epi-
demic European clones I (RUH875) and II (RUH134) [5,6]
were included in the study for comparison.
Antimicrobial susceptibility testing
Antimicrobial agents tested were ampicillin–sulbactam (SAM),
piperacillin (PIP), piperacillin–tazobactam (TZP), cefepime
TABLE 1. Characteristics of Acinetobacter strains
Study code
(hospital)
Source (isolation date;
month/day/year)
Study code
(hospital)
Source (isolation date;
month/day/year)
Study code
(hospital)
Source (isolation date;
month/day/year)
1 (A) Respiratory secretions (06/01/04) 35 (C) Urine (04/05/04) 74 (C) Respiratory secretions (05/28/05)
4 (A) Central venous catheter (08/25/04) 37 (C) Central venous catheter (04/07/05) 75 (C) Wound swab (05/17/05)
5 (A) Respiratory secretions (06/15/04) 38 (C) Respiratory secretions (04/21/05) 76 (C) Respiratory secretions (05/30/05)
6 (A) Central venous catheter (08/02/04) 40 (C) Respiratory secretions (03/29/05) 77 (C) Respiratory secretions (06/09/05)
7 (A) Central venous catheter (07/29/04) 41 (C) Respiratory secretions (02/14/05) 78 (C) Urine (06/11/05)
8 (B) Respiratory secretions (05/06/04) 42 (C) Urine (04/18/05) 79 (C) Respiratory secretions (05/03/05)
9 (B) Blood culture (05/08/04) 43 (C) Respiratory secretions (07/12/04) 105 (C) Cerebrospinal ﬂuid (06/27/05)
10 (B) Respiratory secretions (05/09/04) 44 (C) Respiratory secretions (07/26/04) 80 (D) Wound swab (01/24/05)
11 (B) Respiratory secretions (05/15/04) 46 (C) Respiratory secretions (03/21/05) 81 (D) Respiratory secretions (02/15/04)
12 (B) Respiratory secretions (05/18/04) 48 (C) Respiratory secretions(03/29/05) 82 (D) Wound swab (04/12/04)
13 (B) Respiratory secretions (05/28/04) 50 (C) Respiratory secretions (01/07/04) 83 (D) Central venous catheter (10/14/04)
14 (B) Respiratory secretions (06/14/04) 51 (C) Respiratory secretions (11/16/04) 84 (D) Urine (03/19/04)
16 (B) Respiratory secretions (06/21/04) 52 (C) Respiratory secretions (07/05/04) 85 (D) Respiratory secretions (03/04/04)
17 (B) Respiratory secretions (07/06/04) 53 (C) Urine (03/09/04) 86 (D) Urine (04/11/04)
19 (B) Respiratory secretions (09/15/04) 54 (C) Respiratory secretions (01/19/04) 87 (D) Central venous catheter (07/06/04)
20 (B) Respiratory secretions (09/28/04) 55 (C) Urine (01/13/04) 88 (D) Respiratory secretions (03/02/04)
21 (B) Central venous catheter (09/28/04) 57 (C) Respiratory secretions (02/25/04) 89 (D) Respiratory secretions (02/11/05)
22 (B) Respiratory secretions (08/18/04) 58 (C) Blood culture (06/16/04) 90 (D) Wound swab (03/03/05)
23 (B) Respiratory secretions (10/11/04) 60 (C) Respiratory secretions (07/26/04) 91 (D) Central venous catheter (03/10/05)
24 (B) Blood culture (10/16/04) 61 (C) Respiratory secretions (03/15/04) 92 (D) Blood culture (05/10/05)
25 (B) Urine (11/23/04) 62 (C) Wound swab (03/19/04) 93 (D) Central venous catheter (10/04/04)
26 (B) Environmental, laryngoscope (05/28/04) 63 (C) Respiratory secretions (06/21/04) 94 (D) Blood culture (10/01/04)
27 (B) Environmental, ventilator (06/14/04) 64 (C) Respiratory secretions (03/24/05) 95 (D) Respiratory secretions (10/26/04)
28 (B) Environmental, laryngoscope (06/21/04) 66 (C) Respiratory secretions (10/19/04) 96 (D) Central venous catheter (08/05/04)
29 (B) Central venous catheter (07/19/04) 67 (C) Environmental, cabinet (06/16/04) 73 (E) Respiratory secretions (05/28/05)
30 (B) Respiratory secretions (07/15/04) 68 (C) Environmental, trolley (06/21/04) 97 (F)a Respiratory secretions (06/25/05)
31 (B) Respiratory secretions (07/19/04) 69 (C) Environmental, trolley (07/05/04) 98 (F) Respiratory secretions (06/07/05)
32 (B) Respiratory secretions (07/13/04) 70 (C) Environmental,ventilator (07/12/04) 99 (F) Respiratory secretions (11/19/04)
33 (C) Wound swab (03/10/04) 71 (C) Environmental, desk surface (07/26/04) 100 (F) Respiratory secretions (03/01/05)
34 (C) Respiratory secretions (09/30/04) 72 (C) Environmental, desk surface (07/26/04) 115 (G)a Blood culture (06/10/05)
aA. baumannii index strains [19,20]; study code 115 is equivalent to strain ACICU [13].
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(FEP), ceftazidime (CAZ), aztreonam (ATM), imipenem (IPM),
meropenem (MEM), amikacin (AMK), gentamicin (GEN),
ciproﬂoxacin (CIP), levoﬂoxacin (LVX), trimethoprim-sulfa-
methoxazole (SXT), colistin (CS), and tigecycline (TIG). For all
antimicromials, except CS and TIG, susceptibility testing was
performed with the Vitek 2 system. MIC results were inter-
preted according to the CLSI breakpoint criteria [21]. TIG and
CS susceptibility was determined by the broth microdilution
method [21]. The MICs of TIG were determined in 96-well
microtiter plates (Costar, Cambridge, MA, USA) containing
freshly prepared Mueller–Hinton broth (Oxoid, Milan, Italy).
The inoculum was adjusted to c. 5 · 105 CFU/mL, and plates
were visually read after incubation for 24-h incubation at
37C. Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC 29213 were used as internal quality control strains.
The US FDA breakpoints approved for Enterobacteriaceae
were applied to deﬁne TIG susceptibility (susceptibility,
£2 mg/L; resistance, ‡8 mg/L). The criteria proposed by Gales
et al. [22] were used for interpretation of CS susceptibility.
The MDR phenotype was deﬁned as diminished susceptibility
to ‡2 of the following drug classes: antipseudomonal cephalo-
sporins, antipseudomonal carbapenems, b-lactam–b-lactamase
inhibitor combinations, antipseudomonal ﬂuoroquinolones and
aminoglycosides [23].
Ampliﬁed ribosomal DNA restriction analysis (ARDRA)
ARDRA was carried out with restriction enzymes AluI, CfoI,
MboI, MspI, and RsaI (Roche, Monza, Italy), as previously
described [24]. Ribosomal (r)DNA restriction patterns were
interpreted according to Dijkshoorn et al. [24] and Van-
eechoutte et al. [25].
Epidemiological typing
Random Ampliﬁed Polymorphic DNA (RAPD) analysis was
performed for all isolates with M13, ERIC-2, DAF4 and dec-
anucleotide primers (Table 2) as previously described
[26,27].
Macrorestriction analysis of ApaI-digested genomes was
performed for a selected group of A. baumannii isolates, rep-
resentative of the different RAPD types and hospitals.
Pulsed-ﬁeld gel electrophoresis (PFGE) was carried out as
previously described [28], using a CHEF mapper (Bio-Rad,
Segrate, Milan, Italy). PFGE proﬁles were interpreted accord-
ing to published criteria [29], with a difference of six bands
or less used to deﬁne epidemiological relatedness.
Electropherograms were analysed either visually or using
the Bionumerics software (Applied Maths, Sint-Martems-
Latem, Belgium). The percentage of pattern similarity
between pairs of isolates was calculated as (number of
shared fragments · 2 · 100)/total number of fragments in
the two samples [30]. The BioNumerics analysis was per-
formed using the Dice coefﬁcient and the unweighted pair
group method of averages (UPGMA) with a 1% tolerance
limit and 1% optimisation. Isolates that clustered with ‡80%
or ‡65% similarity were considered to belong to the same
RAPD or PFGE type, respectively. Within the same RAPD
type, isolates differing by <2 bands were considered sub-
types. Multiplex PCRs for the deﬁnition of A. baumannii
TABLE 2. List of primers used in
the study
Primer Nucleotide sequence (5¢–3¢) Amplicon size (bp) References
intI1-FW CAGTGGACATAAGCCTGTTC 160 [14]
intI1-RV CCCGAGGCATAGACTGTA
intI2-FW TTGCGAGTATCCATAACCTG 288 [14]
intI2-RV TTACCTGCACTGGATTAAGC
intI3-FW GCCTCCGGCAGCGACTTTCAG 979 [32]
intI3-RV ACGGATCTGCCAAACCTGACT
5¢CS GGCATCCAAGCAGCAAG V [14]
3¢CS AAGCAGACTTGACCTGA
16S-FW TGGCTCAGATTGAACGCTGGC @ 1500 [25]
16S-RV TACCTTGTTACGACTTCACCCCA
blaIMP-FW ATGAGCAAGTTATCTGTATTCT 741 [16]
blaIMP-RV TTAGTTGCTTGGTTTTGATGG
blaOXA-23-FW GATCGGATTGGAGAACCAGA 501 [35]
blaOXA-23-RV ATTTCTGACCGCATTTCCAT
blaOXA-24-FW GGTTAGTTGGCCCCCTTAAA 246 [35]
blaOXA-24-RV AGTTGAGCGAAAAGGGGATT
blaOXA-51-FW TAATGCTTTGATCGGCCTTG 353 [35]
blaOXA-51-RV TGGATTGCACTTCATCTTGG
blaOXA-58-FW CGATCAGAATGTTCAAGCGC 528 [34]
blaOXA-58-RV ACGATTCTCCCCTCTGCGC
ISAba1-FW CACGAATGCAGAAGTTG V [36]
ERIC-2 AAGTAAGTGACTGGGGTGAGCG M [26]
M13 GAGGGTGGCGGTTCT M [26]
DAF4 CGGCAGCGCC M [26]
Decanucleotide GCTTGTGAAC M [27]
M13-FW GTAAAACGACGGCCAGT V [33]
M13-RV AACAGCTATGACCATG
M, multiple; V, variable.
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sequence groups 1 and 2 were performed using ompA, csuE
and blaOXA-51-like target genes as described [31].
Integron analysis, cloning and sequencing
Integrons were searched for by PCR with primer pairs tar-
geting the intI1, intI2 or intI3 genes (Table 2), as described
[14,32]. The internal variable region encompassing the gene
cassettes of class 1 integrons was ampliﬁed with primers
5¢-CS and 3¢-CS (Table 2) [14]. For preliminary comparison
of integrons, restriction fragment length polymorphysm
(RFLP) analysis with HinfI (Roche) was performed for the
pool of amplicons generated from each strain with primers
5¢-CS and 3¢-CS. Then, individual integron bands from proto-
typic strains were extracted from agarose, puriﬁed using the
Quiquick gel extraction kit (Qiagen, Milan, Italy), digested
with HinfI, and subjected to electrophoresis to deﬁne integ-
ron-speciﬁc RFLPs. Puriﬁed integron bands were also ligated
into the pDrive plasmid (Qiagen), used to transform E. coli
DH5a competent cells [33], and sequenced. Nucleotide
sequence similarity searches were performed using the
BLAST tool in the GenBank database (http://www.blast.
ncbi.nlm.nih.gov/Blast.cgi).
Identiﬁcation of carbapenem-resistance genes
The presence of the blaIMP, blaOXA-23, blaOXA-24, blaOXA-51,
and blaOXA-58 genes was investigated by PCR as previously
reported [16,34,35] (Table 2). The occurrence of the activat-
ing ISAba1 element upstream of the blaOXA-51 gene was
determined by PCR with the ISAba1F-OXA-51-likeR primer
pair as described [36]. The identity of blaOXA-58 and blaOXA-
24 amplicons was conﬁrmed by direct DNA sequencing.
Results
Identiﬁcation of Acinetobacter genospecies by ARDRA
Eighty-eight of the 90 isolates submitted were deﬁnitively
identiﬁed as A. baumannii, showing the typical ARDRA pro-
ﬁles ‘11123’ (72 isolates; 81.8%) and ‘11121’ (16 isolates;
18.2%) with CfoI, AluI, MboI, RsaI, and MspI, respectively
(Fig. S1). Two isolates provisionally identiﬁed as A. baumannii
were assigned to the Acinetobacter genospecies 10 (study
code 61; ARDRA proﬁle ‘42123’) and 13TU (study code 98;
ARDRA proﬁle ‘21113’).
A. baumannii genotyping and correlation with European
clones I and II
Five distinct RAPD proﬁles obtained with M13 and ERIC-2
primers were visually identiﬁed, while complex proﬁles with
some unresolved bands were generated by DAF4 (Fig. S2).
Unsatisfactory results were obtained using the decanucleo-
tide (data not shown).
The majority of A. baumannii strains were grouped in the
RAPD-1 type (71 isolates including subtype 1a; 80.7%) and
RAPD-2 type (16 isolates including subtype 2a; 18.2%). The
two index strains (study codes 97 and 115) showed identical
RAPD-1 proﬁles (Fig. S2). The dendrograms obtained for
M13, ERIC-2 and DAF4 RAPD ﬁngerprints highlight the two
major A. baumannii clusters, corresponding to RAPD-1 and
RAPD-2 types (Fig. 1). The two groups are deﬁned by simi-
larity thresholds ‡85%, 90% and 80% for primers M13, ERIC-
2 and DAF4, respectively (Fig. 1 and Fig. S2). RAPD-1 and
RAPD-2 types were associated with ARDRA proﬁles ‘11123’
and ‘11121’, respectively. Environmental isolates from hospi-
tals B and C showed the same RAPD-1 type as their clinical
counterparts.
The possible correlation between A. baumannii RAPD-1
and RAPD-2 types and the European epidemic clones I and II
was preliminarily investigated by comparing the RAPD ﬁnger-
prints of selected strains generated using the M13 and ERIC-
2 primers. Signiﬁcant similarity (100–78%, depending on the
primer) was observed between representative RAPD-1 and
RAPD-2 type isolates and the European clones II and I,
respectively (Fig. 2).
Assuming that A. baumannii isolates with identical RAPD
proﬁles from each hospital represent a single strain, a total
of 12 A. baumannii strains was selected for comparative PFGE
analysis with the reference European clones I and II. Two
major ApaI macrorestriction proﬁles (pulsotypes 1 and 2)
were identiﬁed, corresponding to RAPD-1 and RAPD-2
types, respectively (Fig. 2). Interpretation of PFGE patterns
conﬁrmed the relationship between A. baumannii pulsotypes
1 and 2 and the European clone II and I, respectively (Fig. 2),
which formed two clusters deﬁned by the similarity thresh-
old ‡65% (data not shown).
Multiplex PCRs for identiﬁcation of sequence groups
yielded the 111 and 222 allelic proﬁles (corresponding to
sequence types 1 and 2, respectively) for strains belonging to
RAPD types 1 and 2, consistent with their genetic related-
ness with European clones II and I, respectively (Fig. 2).
Antimicrobial susceptibility
The comparison of antibiotic resistance proﬁles between
A. baumannii isolates belonging to RAPD-1 and RAPD-2 types
is shown in Fig. 3. A. baumannii RAPD-1 and RAPD-2 isolates
showed a common MDR proﬁle characterized by resistance
to PIP, TZP, CAZ, ATM, CIP, LVX and FEP.
All RAPD-1 type isolates were resistant to carbapenems
(IPM and MEM), while RAPD-2 isolates were all susceptible.
The MICs of IPM for resistant isolates were in the range of
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FIG. 1 RAPD analysis of 90 Acinetobacter isolates and correlation with ARDRA types. (a) Clustering relationships inferred from RAPD analysis
with M13, ERIC-2, and DAF4 primers. The dendrogram was generated with BioNumerics (Applied Maths) using the unweighted pair-group
method with arithmetic averages (UPGMA) and the Dice coefﬁcient. Dotted lines denote the threshold values set to deﬁne RAPD types. The
strain code, as presented in Table 1, is shown on the right. (b) Association of RAPD types with ARDRA proﬁles.
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16–32 mg/L, except for one RAPD type 1a strain (study
code 50) which showed an MIC value of 128 mg/L.
All A. baumannii isolates were susceptible to CS, except
the only RAPD type 1a strain (study code 50) showing resis-
tance (MIC > 32 mg/L). Interestingly, a signiﬁcant percentage
of type 1 and type 2 A. baumannii isolates were susceptible
to SAM (48.6% and 71.4% respectively) at MICs £ 4–8 mg/L.
A. baumannii isolates belonging to both types 1 and 2 were
FIG. 2 Comparison of DNA ﬁngerprints among the European epidemic clones I (strain RUH875) and II (strain RUH134) and representative Aci-
netobacter baumannii strains. (a) RAPD proﬁles obtained with M13 and ERIC-2 primers for strains representative of different hospitals and RAPD
types, and reference strains RUH875 and RUH134. The 100 bp DNA size standard (Promega, Milan, Italy) is shown in lanes M. (b) Macrorestric-
tion analysis with enzyme ApaI of 12 representative A. baumannii isolates. The study code or strain designation and the hospital from which the
strain originated are indicated above each lane. RAPD types, pulsotypes, and sequence groups are indicated below each lane. The RAPD-4 type
corresponds to pulsotype 3. Ec, European clone; ND, not determined.
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resistant to TIG at a relatively high rate (27.4% overall,
including intermediate and fully resistant isolates; Fig. 3). The
MIC50 values were 2 and 4 mg/L for type 1 and type 2 iso-
lates, respectively.
Characterization of integrons and antibiotic resistance
determinants
The 160 bp DNA fragment internal to the class 1 integrase
(intI1) gene was ampliﬁed from 84 (95.4%) A. baumannii iso-
lates, with the exception of RAPD-1a, -2a, and -4 types. All
isolates were negative for class 2 and class 3 integrons (data
not shown).
Ampliﬁcation products of c. 2.2 and 2.5 kb were obtained
with the 5¢-CS, 3¢-CS primer pair from A. baumannii isolates
belonging to RAPD-1 and RAPD-2 types, respectively. An
additional amplicon of 0.75 kb was common to both types.
Products of 0.7 and 3.0 kb were obtained for the European
clones I (strain RUH875) and II (strain RUH134), respectively
(Fig. S3), corresponding in size to those previously identiﬁed
by Nemec et al. [11]. No ampliﬁcation products were
obtained from A. baumannii strains with RAPD types 1a, 2a,
and 4 consistent with the absence of the intI1 gene in these
strains (data not shown).
A preliminary RFLP analysis showed the same integron
content for all strains of the same RAPD type, and substan-
tial similarity between the 2.5-kb integron of type 2 strains
and the 3.0-kb integron of the European clone II (Fig. S3 and
Table S1).
Sequencing of the cloned 2.2-kb variable region revealed
the presence of three gene cassettes: the aacA4 gene encod-
ing an AAC(6’)-Ib aminoglycoside acetyltranferase, an open
reading frame (ORF) encoding an unknown product, and the
blaOXA-20 gene encoding a class D b-lactamase (Fig. 4).
Sequence analysis of the cloned 2.5 kb variable region
revealed the presence of four gene cassettes: the aacC1 gene
encoding an AAC(3)-Ia aminoglycoside acetyltransferase, two
ORFs for unknown products, and the aadA1a gene encoding
FIG. 3 Antibiotic resistance among 87 Acinetobacter baumannii strains belonging to RAPD-1 (black) and RAPD-2 (white) types. Isolates showing
an intermediate level of susceptibility were classiﬁed as resistant. (a) SAM, ampicillin-sulbactam; PIP, piperacillin; TZP, piperacillin-tazobactam;
FEP, cefepime; CAZ, ceftazidime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; CIP, ciproﬂoxacin;
LVX, levoﬂoxacin; SXT, trimethoprim-sulfamethoxazole; CS, colistin; TIG, tigecycline.
FIG. 4 Comparison of integron structures found in the prototypic
European clone II and in Acinetobacter baumannii RAPD types 1 and
2. The structure of the 3.0-kb (a), 2.5-kb (b), and 2.2-kb (c) class 1
integrons detected in the A. baumannii European clone II (strain
RUH134) and RAPD types 2 and 1, respectively, was inferred from
DNA sequence analysis. Coding sequences (not to scale) are indi-
cated by arrows and named according to ref. [44]; the attC (recom-
bination site) and attI (attachment site) sites are shown as black and
gray rectangles, respectively. Arrowheads indicate the position and
direction of primers used in various combinations for PCR analysis.
Horizontal lanes indicate the size of PCR products. The dotted line
denotes the possible event of orfX insertion/deletion.
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an AAD(3’)-Ia aminoglycoside adenyltransferase. Intriguingly,
the 3.0 kb integron of strain RUH134 showed substantial
similarity with the 2.5 kb integron found in type 2 isolates
(Fig. 4). No homology with known resistance genes was
observed for the 0.75-kb amplicon sequence, which probably
originates from mispriming of oligonucleotides 5¢-CS and
3¢-CS.
The antibiotic resistance genes found in the 2.2 and 2.5 kb
integrons partly explain the antibiotic resistance proﬁles
observed for type 1 and 2 A. baumannii strains. The presence
of the aacA4 genes in the 2.2 kb integron was associated
with resistance to AMK, while the presence of the aacC1
gene in the 2.5 kb integron was associated with resistance to
GEN. However, the absence of these integron cassettes did
not imply susceptibility to AMK and GEN.
A search for carbapenem resistance determinants showed
that all isolates were negative for both blaOXA-23 and blaIMP
genes, and positive for the blaOXA-51 gene, irrespective of
their resistance or susceptibility to carbapenems. The pres-
ence of the ISAba1 element upstream of the blaOXA-51 gene
was not detected in any isolate. Seventy-one carbapenem-
resistant A. baumannii isolates, including 70 RAPD-1 isolates
and one RAPD-4 isolate, were positive for the blaOXA-58
gene, while all carbapenem-susceptible A. baumannii isolates,
mostly belonging to the RAPD-2 type, were not. The
blaOXA-24 gene was detected in the single A. baumannii isolate
belonging to RAPD type 1a (study code 50). This strain dif-
fered from all other carbapenem-resistant A. baumannii iso-
lates in that it was very high-level resistant to IPM (128 mg/L
vs. 16-32 mg/L).
Hospital distribution of A. baumannii type 1 and type 2
isolates
Molecular typing revealed the prevalence of two epidemic
clones accounting for 98.9% of all A. baumannii isolates
(Fig. 5), as also documented for several A. baumannii out-
breaks in Europe [37]. The dominant A. baumannii clone,
referred to as type 1, was isolated from all hospitals (A–G)
and accounted for 80.7% of isolates (Fig. 5). Type 1 strains
were also isolated from the ICU environment associated
with infection. Notably, both A. baumannii index strains from
previous ICU outbreaks in Rome (hospitals F and G; [19,20])
belonged to type 1. The present investigation also shows
that type 1 strains have been isolated from patients cared
for in the ICU of hospital F several months before the onset
of the outbreak (July–September 2005) [19], raising serious
concern as to the persistence of this epidemic strain in the
entire Rome urban area. The second A. baumannii clone,
referred to as type 2, accounted for 18.2% of isolates
(Fig. 5), and prevailed in hospital D (11 of 17 isolates) while
coexisting with type 1 in hospital C (ﬁve of 37 isolates).
Temporal clustering was noted in hospitals A, B, and C
during the warmer season (May–October 2004; Fig. 5).
Discussion
Understanding the global epidemiology of A. baumannii infec-
tion has become a public health priority since MDR epidemic
clones spread in several western countries and community-
acquired A. baumannii pneumonia emerged as a novel clinical
entity [1,2]. This calls for surveillance on both a national and
international scale. Although A. baumannii strains related to
European clones I and II have sporadically been documented
in Italian hospitals [8,10,11,13], no systematic survey of
A. baumannii epidemiology is available from Italy. Therefore,
the molecular epidemiology and genetic basis of antibiotic
resistance was investigated in a representative collection of
MDR A. baumannii strains isolated in Rome during an 18-
month period.
Since commercial systems can occasionally fail in A. bau-
mannii identiﬁcation, all isolates were ﬁrst investigated at the
genospecies level by ARDRA [24], and a satisfactory rate
(97.8%) of species identiﬁcation was found by collaborating
centres. Interestingly, ARDRA differentiated A. baumannii into
two main groups, accounting for 81.8% (type ‘11123’) and
18.2% (type ‘11121’) of A. baumanni isolates.
Here, evidence that MDR A. baumannii strains isolated
from ICUs in Rome belong to two predominant types,
genetically related to the European clones I and II is
provided. In fact, the generation of similar DNA banding pat-
terns between A. baumannii types 1 and 2 and the European
FIG. 5 Hospital distribution of A. bau-
mannii clinical and environmental isolates
during the 18-month investigation per-
iod. Asterisks denote A. baumanii index
strains [19,20].
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clones II and I, respectively, strongly argues for their genetic
similarity. Accordingly, the same sequence group was deter-
mined for the European clone II and all type 1 strains, as well
as for the European clone I and all type 2 strains. Minor dif-
ferences (concerning <2 bands) in the RAPD ﬁngerprints
were observed, plausibly arising from ongoing diversiﬁcation
in space and time from the reference strains RUH134 (Euro-
pean clone II) and RUH875 (European clone I) which were
both isolated in early 1980s [6]. Likewise, the criterion
applied to correlate PFGE types (<6 band difference [29]) is
stringent enough to ensure the genetic relatedness. Thus,
the study isolates may represent a subgroup within the Euro-
pean clonal lineages I and II, as similarly suggested by Da Silva
et al. [38] for Portuguese MDR A. baumannii isolates. Nota-
bly, the propensity of A. baumannii to evolve through exten-
sive genome rearrangement is corroborated by genomic
studies showing the ability of A. baumannii to acquire exoge-
nous DNA, primarily carrying pathogenicity and drug-resis-
tance islands [13,39–41]. Horizontal gene transfer events
could result in diversiﬁcation of molecular ﬁngerprints, as
suggested by this study.
Considering the broad spectrum of antibiotic resistance
observed among MDR A. baumannii, it is worth noticing that
a fairly high percentage of A. baumannii isolates belonging to
both type 1 (48.6%) and type 2 (71.4%) was susceptible to
the combination of ampicillin and sulbactam, in spite of the
high overall resistance to other b-lactams. As previously
demonstrated by Corbella et al. [42], the inhibitory effect of
SAM on MDR A. baumannii is likely to be attributed to the
activity of sulbactam alone, independent of b-lactamase inhi-
bition. Hence, the present data suggest that SAM should be
taken into account in the choice of commercial cards for use
in A. baumannii identiﬁcation and susceptibility testing, espe-
cially when alternative therapeutic options are needed to
treat carbapenem-resistant A. baumannii infections.
There has been considerable concern regarding the recent
reports of nosocomial outbreaks of carbapenem-resistant
A. baumannii in Rome [18–20], and several studies
documented the emergence of the carbapenem-hydrolysing
b-lactamase blaOXA-58 gene in clinical A. baumannii isolates
[18,19,34]. The present ﬁndings demonstrate that the
blaOXA-58 gene accounts for MEM and IPM resistance in 98.6%
of the carbapenem-resistant A. baumannii type 1 isolates, irre-
spective of the hospital source. Moreover, the single CS-resis-
tant isolate, classiﬁed as RAPD-1a type, carried the blaOXA-24
gene and showed high-level resistance to IPM. This strain is
likely to be derived from the MDR type 1 lineage through
evolution towards pan-resistance, resulting in susceptibility to
TIG only. Overall, TIG resistance was observed for 22.8% and
50% of A. baumannii isolates belonging to types 1 and 2,
respectively. This result is worrying, since TIG has recently
been introduced in the Italian market and all isolates were
obtained from patients who had never been treated with TIG.
Moreover, individual type 1 and type 2 A. baumannii isolates
displayed high variability with regard to TIG susceptibility,
likely reﬂecting intraclonal diversiﬁcation at the level of the
presence and/or expression of TIG resistance mechanisms,
such as efﬂux pumps [43].
The high rate of carbapenem and TIG resistance and the
risk of emergence of pan-resistance among isolates related
to the European epidemic clone II deserve consideration in
clinical practice, infection surveillance, and hospital policy of
antibiotic administration.
Further insight into the antimicrobial resistance determi-
nants in A. baumannii isolates was provided by characteriza-
tion of integrons, which were detected in 98.6% and 87.5%
of type 1 and 2 strains, respectively, being absent only in
RAPD-1a and RAPD-2a variants. However, a different array
of gene cassettes was observed in A. baumannii integrons,
with type 1 and type 2 isolates carrying the 2.2 and 2.5 kb
variable regions, respectively. The gene content of both
integrons is predicted to account for different aminoglyco-
side resistance patterns. Similar gene cassette arrays were
previously identiﬁed in class 1 integrons of epidemic A. bau-
mannii strains from different European countries [11,37,44].
Although integrons of A. baumannii outbreak strains appear
to host a limited number of gene cassette arrangements, iso-
lates of the same genotype may not only be associated with
different integrons, but unrelated isolates of different geno-
types may also contain the same integron [11,32,44]. Integ-
ron rearrangement, or exchange, can be imagined to explain
the structural similarity observed between the 3.0 kb integ-
ron of the prototypic European clone II strain RUH134 and
the 2.5 kb integron of type 2 strains, which are indeed
related to the European clone I, rather than clone II. In fact,
the 3.0-kb integron found in the prototypic European
clone II (emerged in the early 1980s [11]) could generate
the 2.5-kb integron (emerged in the late 1990s [44]) by exci-
sion of one the duplicate OrfX cassettes (Fig. 4).
This process could have occurred either by integrase-
mediated or by homologous recombination, leading to loss
of one of the duplicate cassettes in the ancestor integron.
Since strains belonging to both clonal lineages can coexist
in the same hospital [45], it was hypothesized that horizontal
transfer of entire integron structures between lineages may
account for the variability of integrons carried by genetically
related strains.
In conclusion, evidence of the emergence of two epidemic
MDR A. baumannii clones, genetically related to the European
clones I and II and responsible for infections in ICUs in the
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main hospitals of the Rome urban area is provided. Although
important questions concerning the origin and the ‘epidemic
success’ of these clones remain unanswered, it must be
emphasized that A. baumannii isolates of type 1 were found
in all hospitals. Early recognition of these epidemic clones is
therefore recommended in order to devise effective preven-
tion and control measures for A. baumannii infection in ICUs.
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